Ademi LLP probes Nuvalent's $10.6B deal with GSK over fair price and board duties.

Ademi LLP is investigating Nuvalent's $10.6 billion acquisition by GSK, focusing on whether the deal offers a fair price to public shareholders and if Nuvalent's board fulfilled their fiduciary duties. Shareholders will receive $124 per share, but concerns include substantial benefits to insiders and restrictive terms limiting competing bids. The investigation aims to protect shareholder rights amid the transaction. Investors interested can contact Ademi LLP for more information.